NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free EBS Stock Alerts $6.17 +0.13 (+2.15%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$5.75▼$6.2850-Day Range$1.86▼$6.6752-Week Range$1.42▼$9.96Volume1.68 million shsAverage Volume2.04 million shsMarket Capitalization$323.31 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Emergent BioSolutions alerts: Email Address Emergent BioSolutions MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside19.0% Downside$5.00 Price TargetShort InterestHealthy11.81% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$75,831 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.98) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector429th out of 914 stocksPharmaceutical Preparations Industry192nd out of 429 stocks 1.0 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days.Read more about Emergent BioSolutions' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.81% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently decreased by 1.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 2.0 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Emergent BioSolutions this week, compared to 2 articles on an average week.Search InterestOnly 21 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows5 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,831.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent BioSolutions' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.98) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent BioSolutions' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Emergent BioSolutions Stock (NYSE:EBS)Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More EBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Stock News HeadlinesJune 7, 2024 | insidertrades.comKathryn C. Zoon Sells 10,000 Shares of Emergent BioSolutions Inc. (NYSE:EBS) StockJune 14 at 2:36 AM | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Stock Passes Above Two Hundred Day Moving Average of $2.88June 8, 2024 | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) Director Sells $61,100.00 in StockJune 8, 2024 | americanbankingnews.comTraders Buy Large Volume of Put Options on Emergent BioSolutions (NYSE:EBS)June 6, 2024 | globenewswire.comEmergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness DayMay 21, 2024 | investorplace.com7 Stocks to Buy Immediately Following Strong EarningsMay 16, 2024 | investorplace.comVice Stock Vanguards: 3 Sin Stocks Delivering Heavenly ReturnsMay 10, 2024 | globenewswire.comEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024May 2, 2024 | msn.comEmergent BioSolutions gains as results top estimates, co to cut 300 jobsMay 2, 2024 | msn.comEmergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?May 2, 2024 | bizjournals.comWhy this Gaithersburg biotech's stock is surgingMay 2, 2024 | finance.yahoo.comQ1 2024 Emergent BioSolutions Inc Earnings CallMay 2, 2024 | investorplace.comEmergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job CutsMay 2, 2024 | finance.yahoo.comEmergent BioSolutions Inc (EBS) (Q1 2024) Earnings Call Transcript Highlights: A Strong Start ...May 2, 2024 | investorplace.comWhy Is Emergent BioSolutions (EBS) Stock Up 57% Today?May 2, 2024 | investorplace.comEBS Stock Earnings: Emergent BioSolutions Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | bizjournals.comGaithersburg biotech to shutter Baltimore facility amid cost-cuttingMay 1, 2024 | bizjournals.comEmergent BioSolutions eliminating 300 jobs, shutting down multiple facilitiesMay 1, 2024 | finance.yahoo.comNarcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close FacilitiesMay 1, 2024 | finance.yahoo.comEmergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...May 1, 2024 | globenewswire.comEmergent BioSolutions Reports First Quarter 2024 Financial ResultsMay 1, 2024 | reuters.comEmergent BioSolutions to lay off about 300 employeesMay 1, 2024 | globenewswire.comEmergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial PositionMay 1, 2024 | globenewswire.comEmergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to NaloxoneMay 1, 2024 | markets.businessinsider.comEmergent BioSolutions earnings: here's what Wall Street expectsSee More Headlines Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees1,600Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside-19.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-47.68% Pretax Margin-47.12% Return on Equity-18.53% Return on Assets-7.14% Debt Debt-to-Equity Ratio0.67 Current Ratio1.08 Quick Ratio0.55 Sales & Book Value Annual Sales$1.16 billion Price / Sales0.28 Cash Flow$0.90 per share Price / Cash Flow6.87 Book Value$12.51 per share Price / Book0.49Miscellaneous Outstanding Shares52,402,000Free Float51,773,000Market Cap$323.32 million OptionableOptionable Beta1.64 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Richard S. Lindahl M.B.A. (Age 60)Executive VP, CFO & Treasurer Comp: $1.02MMs. Jennifer L. Fox (Age 51)Executive VP of External Affairs, General Counsel & Corporate Secretary Comp: $975.84kMs. Coleen Glessner (Age 53)Executive Vice President of Global Quality and Ethics & Compliance Comp: $959.37kMr. Paul A. Williams (Age 57)Senior Vice President of Products Business Comp: $846.97kMr. Joseph C. Papa Jr. (Age 68)CEO, President & Director Michelle PepinSenior VP & Chief Human Resource OfficerMs. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerDr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentWilliam HartzelSenior Vice President of Manufacturing & BioservicesMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsKathryn C ZoonSold 10,000 sharesTotal: $61,100.00 ($6.11/share)Kathryn C ZoonSold 1,830 sharesTotal: $8,436.30 ($4.61/share)Cetera Advisors LLCBought 169,317 shares on 5/24/2024Ownership: 0.323%Kathryn C ZoonSold 1,089 sharesTotal: $6,294.42 ($5.78/share)Tidal Investments LLCBought 13,352 shares on 5/17/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions EBS Stock Analysis - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price target for 2024? 2 brokerages have issued 12-month target prices for Emergent BioSolutions' shares. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 19.0%. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2024? Emergent BioSolutions' stock was trading at $2.40 at the beginning of 2024. Since then, EBS shares have increased by 157.1% and is now trading at $6.17. View the best growth stocks for 2024 here. Are investors shorting Emergent BioSolutions? Emergent BioSolutions saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 6,040,000 shares, a drop of 15.3% from the April 30th total of 7,130,000 shares. Based on an average daily volume of 4,800,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 12.0% of the company's shares are sold short. View Emergent BioSolutions' Short Interest. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our EBS earnings forecast. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Wednesday, May, 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of ($3.65) by $4.24. The biopharmaceutical company had revenue of $300.40 million for the quarter. Emergent BioSolutions had a negative net margin of 47.68% and a negative trailing twelve-month return on equity of 18.53%. During the same quarter in the prior year, the company earned ($3.17) EPS. What ETFs hold Emergent BioSolutions' stock? ETFs with the largest weight of Emergent BioSolutions (NYSE:EBS) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) and Schwab Fundamental U.S. Small Company Index ETF (FNDA).Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ). What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions issued an update on its second quarter 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.0 million-$210.0 million, compared to the consensus revenue estimate of $244.5 million. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.51%), Assenagon Asset Management S.A. (1.60%), Los Angeles Capital Management LLC (0.37%), Cetera Advisors LLC (0.32%), BNP Paribas Financial Markets (0.31%) and Susquehanna Fundamental Investments LLC (0.23%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:EBS) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.